New hope for pancreatic cancer: targeted drug combo enters human testing

NCT ID NCT07377045

Recruiting now Disease control Sponsor: Oncomatryx Biopharma S.L. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called OMTX705, which targets a protein on cancer cells, combined with standard chemotherapy and an immunotherapy for people with advanced pancreatic cancer that has spread. The study will enroll 69 participants to first find the safest dose of OMTX705, then compare the combination against chemotherapy alone. The goal is to see if the new mix can shrink tumors or control the disease better than current treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OMTX705 (an antibody-drug conjugate targeting fibroblast activation protein) combined with gemcitabine, nab-paclitaxel, and tislelizumab
What this could lead to: If successful, this could point toward a new combination treatment that shrinks tumors or slows progression in advanced pancreatic cancer, a disease with few options.
What could go wrong: This is an early Phase 1b trial with only 69 participants, focused on safety and dosing. It is too small and early to know if the combination works better than standard care, and side effects from the new drug are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC ADENOCARCINOMA METASTATIC

Contacts and locations

Locations

Beth Israel Deaconess Medical Center (BIDMC)
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
Clinica Universidad de Navarra (CUN)
RECRUITING

Pamplona, 31008, Spain
Hospital Clínico Universitario de Santiago - CHUS
NOT_YET_RECRUITING

Santiago de Compostela, 15706, Spain
Hospital Universitario 12 Octubre
RECRUITING

Madrid, 28041, Spain
Hospital Universitario Donostia
NOT_YET_RECRUITING

Donostia / San Sebastian, 20014, Spain
Hospital Universitario Vall d'Hebron (VHIO)
NOT_YET_RECRUITING

Barcelona, 08035, Spain
ICO- Hospitalet Catalan Institute of Oncology
RECRUITING

L'Hospitalet de Llobregat, 08908, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.